Insider Buying Sparks Interest: Recent discussions on X about Standard BioTools Inc. (LAB) have centered on significant insider purchases by a director, with transactions totaling over $500,000 in the past week. Many users see this as a potential signal of confidence in the company’s future. This buzz has drawn attention to LAB’s stock price movements and strategic direction.
Mixed Market Views: While some on X highlight LAB’s position at a key demand zone with potential for a sharp recovery, others express caution over a possible downtrend if momentum falters. Posts also mention volatile trading activity, with spikes in volume fueling speculation. The chatter reflects a divided outlook on the stock’s near-term trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Standard BioTools Inc. Insider Trading Activity
Standard BioTools Inc. insiders have traded $LAB stock on the open market 24 times in the past 6 months. Of those trades, 24 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LAB stock by insiders over the last 6 months:
- PARTNERS MASTER FUND, L.P. CASDIN has made 24 purchases buying 12,708,220 shares for an estimated $16,303,017 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Standard BioTools Inc. Revenue
Standard BioTools Inc. had revenues of $19.6M in Q3 2025. This is a decrease of -11.47% from the same period in the prior year.
You can track LAB financials on Quiver Quantitative's LAB stock page.
Standard BioTools Inc. Hedge Fund Activity
We have seen 67 institutional investors add shares of Standard BioTools Inc. stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MAK CAPITAL ONE LLC added 10,334,384 shares (+184.6%) to their portfolio in Q3 2025, for an estimated $13,434,699
- TIKVAH MANAGEMENT LLC added 3,551,152 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,616,497
- MIRABELLA FINANCIAL SERVICES LLP removed 3,434,387 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,464,703
- CASDIN CAPITAL, LLC added 1,483,220 shares (+1.9%) to their portfolio in Q3 2025, for an estimated $1,928,186
- LONG FOCUS CAPITAL MANAGEMENT, LLC added 1,292,804 shares (+12.8%) to their portfolio in Q3 2025, for an estimated $1,680,645
- KENT LAKE PR LLC removed 1,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,300,000
- MILLENNIUM MANAGEMENT LLC removed 907,230 shares (-38.4%) from their portfolio in Q3 2025, for an estimated $1,179,399
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Standard BioTools Inc. Government Contracts
We have seen $1,045,578 of award payments to $LAB over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- NRR; NIEHS/DIR/BORTNER; CYTOF XT/HYPERION XTI IMAGING SYSTEM UPGRADE: $507,000
- HIGH THROUGHPUT NANOLITER INTEGRATED FLUIDIC CIRCUIT GENOMICS SYSTEM: $136,842
- PM&R HYPERION TISSUE IMAGER AND HELIOS CYTOF SERVICE: $128,492
- LAB INSTRUMENTS MAINTENANCE: $70,597
- EO14042 HELIOS PREMIUM SERVICE PLAN, HELIOS S/N D16-0189: $56,206
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
